Clinical Trial

A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Protocol Amendment History 3 changes
critical Phase changed: Phase 2 -> Phase 1/2 2026-04-21
critical Primary endpoint(s) modified 2026-04-21
minor Trial arms changed: 1 -> 2 2026-04-21
Trial Details
NCT Number NCT07313852
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Amgen, Pfizer
Conditions B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL
Enrollment 26 participants
Start Date 2026-09
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11